SecBot SecBot
8-K ·Filed Jun 23, 2026

URGN

UroGen Pharma Ltd.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001437749-26-021442
8-K context-dependent: Items 3.03, 5.02
Actionable Insight • Neutral

This is a routine post-annual-meeting 8-K with no material financial or operational content. The increased share reserve for equity compensation is standard and not immediately dilutive. Monitor the next earnings release for business momentum and potential equity grant activity.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$35.42
T+0 close · Jun 23, 2026 · via day close
Latest settled
+24.08%
T+60 · $43.95
Vs SPY
+21.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 24 $35.42entry
  2. T+1 · 5mo ago −2.94%α −3.08% · $34.38
  3. T+5 · 5mo ago +7.11%α +5.41% · $37.94
  4. T+20 · 4mo ago +18.75%α +16.81% · $42.06
  5. T+60 · 2mo ago +24.08%α +21.24% · $43.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

UroGen Pharma held its 2026 annual meeting of shareholders on June 22, 2026. Shareholders approved election of all 7 director nominees, amendments to the articles of association (tying shareholder proposals to Israeli Companies Law requirements), an amendment to the non-employee director and officer compensation policy regarding D&O insurance, and an amendment to the 2017 equity incentive plan increasing authorized shares by 1,000,000. All proposals received majority support. The filing is a routine post-meeting report with no financial data or business updates.

Key Facts

  • Shareholders elected 7 directors to serve until the next annual meeting; all received substantial majority votes.
  • Proposal 2 (Amended and Restated Articles) passed with 19,306,222 For vs 9,007,528 Against.
  • Proposal 3 (Compensation Policy Amendment) passed with 26,089,418 For vs 2,182,017 Against.
  • Proposal 4 (2017 Amended Plan) passed, increasing the share reserve by 1,000,000 shares to a total of 9,750,167 shares.
  • Proposal 5 (advisory vote on executive compensation) passed with 25,125,846 For vs 3,186,040 Against.
  • Proposal 6 (ratification of PricewaterhouseCoopers LLP as auditor) passed with 36,778,509 For vs 90,799 Against.
  • No financial results, guidance, or business changes were disclosed in this filing.

Financial Impact

No financial impact disclosed in filing. The amendment to the 2017 Plan increases share authorization by 1,000,000 shares, but no awards were granted or priced.

share count (authorized)

Risk Factors

  • Approved increase in authorized shares for equity plan could lead to future dilution if awards are granted aggressively.
  • No business updates or financial guidance provided, filing offers no catalyst for near-term price movement.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-021442
Exhibit: ex_979764.htm0001437749-26-021442
Exhibit: ex_979763.htm0001437749-26-021442
Document: urgn20260622_8k.htm0001437749-26-021442
Document: 0001437749-26-021442-index-headers.html0001437749-26-021442
Document: 0001437749-26-021442-index.html0001437749-26-021442
Document: 0001437749-26-021442.txt0001437749-26-021442

Track record

16 reports on URGN

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
  2. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  3. Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
  4. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
  6. Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
  7. Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
  9. Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
  10. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 23, 2026